Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489239 · ClinicalTrials.gov registry record · Phase 3
Entecavir to TAF Switch
A Phase 3 study of Hepatitis B, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT03489239 is a Phase 3 study of Hepatitis B that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 27 participants, below the 1,628-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03489239, a Phase 3 study of Hepatitis B, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
Conditions Studied
Interventions
- DRUG Tenofovir Alafenamide
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-11-16 |
| Est. Completion | 2020-09-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03489239
The ClinicalTrials.gov registry entry for NCT03489239 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,628-participant average among 32 other Hepatitis B trials with a reported enrollment target (98% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir Alafenamide is the first listed.
NCT03489239 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03489239 about?
NCT03489239 is a clinical study titled "Entecavir to TAF Switch". A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
What is the current status of trial NCT03489239?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2017-11-16. Estimated completion is 2020-09-16.
What conditions does trial NCT03489239 study?
This clinical trial studies the following conditions: Hepatitis B.
What interventions are being tested in trial NCT03489239?
The interventions under investigation include: Tenofovir Alafenamide (DRUG).
Who is sponsoring clinical trial NCT03489239?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03489239 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
COMPLETED · Phase 3
-
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
COMPLETED · Phase 3
-
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
COMPLETED · Phase 3
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.